Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis